CRF Receptors in Anxiety and Depression: A New Selective CRF1 Agonist Tool Called Cortagine

A novel selective CRF1 agonist (cortagine) was developed to dissect CRF receptor roles, confirming CRF1 drives anxiety while CRF2 mediates stress recovery — enabling more precise stress receptor pharmacology.

Todorovic, Cedomir et al.·Neuroscience and biobehavioral reviews·2005·Moderate EvidenceReview
RPEP-01092ReviewModerate Evidence2005RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

The novel selective CRF1 agonist cortagine enabled clear dissection of CRF receptor roles: CRF1 activation drives anxiety/depression-like behavior while CRF2 activation promotes stress coping — precise tools for receptor-specific psychiatric drug development.

Key Numbers

How They Did This

review study on neuropeptides, anxiety-mood.

Why This Research Matters

Relevant for neuropeptides, anxiety-mood.

The Bigger Picture

Advances peptide/biomarker research.

What This Study Doesn't Tell Us

See abstract.

Questions This Raises

  • ?Further research needed.
  • ?Clinical translation to evaluate.

Trust & Context

Key Stat:
Key finding The novel selective CRF1 agonist cortagine enabled clear dissection of CRF receptor roles: CRF1 activation drives anxiety/depression-like behavior whi
Evidence Grade:
moderate evidence.
Study Age:
Published in 2005.
Original Title:
The role of CRF receptors in anxiety and depression: implications of the novel CRF1 agonist cortagine.
Published In:
Neuroscience and biobehavioral reviews, 29(8), 1323-33 (2005)
Database ID:
RPEP-01092

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What was studied?

CRF Receptors in Anxiety and Depression: A New Selective CRF1 Agonist Tool Called Cortagine

What was found?

A novel selective CRF1 agonist (cortagine) was developed to dissect CRF receptor roles, confirming CRF1 drives anxiety while CRF2 mediates stress recovery — enabling more precise stress receptor pharmacology.

Read More on RethinkPeptides

Cite This Study

RPEP-01092·https://rethinkpeptides.com/research/RPEP-01092

APA

Todorovic, Cedomir; Jahn, Olaf; Tezval, Hossein; Hippel, Cathrin; Spiess, Joachim. (2005). The role of CRF receptors in anxiety and depression: implications of the novel CRF1 agonist cortagine.. Neuroscience and biobehavioral reviews, 29(8), 1323-33.

MLA

Todorovic, Cedomir, et al. "The role of CRF receptors in anxiety and depression: implications of the novel CRF1 agonist cortagine.." Neuroscience and biobehavioral reviews, 2005.

RethinkPeptides

RethinkPeptides Research Database. "The role of CRF receptors in anxiety and depression: implica..." RPEP-01092. Retrieved from https://rethinkpeptides.com/research/todorovic-2005-the-role-of-crf

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.